Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 10, 2005, Pages 2391-2401

  Skibola, Christine F ^a   Bracci, Paige M ^b   Paynter, Randi A ^a   Forrest, Matthew S ^a   Agana, Luz ^a   Woodage, Trevor ^c   Guegler, Karl ^c   Smith, Martyn T ^a   Holly, Elizabeth A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c APPLIED BIOSYSTEMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 17; CYTOCHROME P450 17A1; CYTOSINE; ESTROGEN; ESTROGEN RECEPTOR; GUANINE; METHIONINE; ORAL CONTRACEPTIVE AGENT; PROLACTIN; PROLACTIN RECEPTOR; THYMIDINE; UNCLASSIFIED DRUG; VALINE;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG USE; ESTROGEN SYNTHESIS; FEMALE; FOLLICULAR LYMPHOMA; GENE LOCUS; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

ADULT; AGED; CATECHOL O-METHYLTRANSFERASE; ESTROGEN RECEPTOR ALPHA; FEMALE; GENETICS, POPULATION; HAPLOTYPES; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROLACTIN; RISK FACTORS; SAN FRANCISCO; STEROID 17-ALPHA-HYDROXYLASE;

EID: 26444587624     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0343     Document Type: Article

References (55)

1. McMurray RW. Estrogen, prolactin, and autoimmunity: actions and interactions. Int Immunopharmacol 2001;1:995-1008.
2. Ben-Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 2002;13:245-50.
3. Jakob F, Tony HP, Schneider D, Thole HH. Immunological detection of the oestradiol receptor protein in cell lines derived from the lymphatic system and the haematopoietic system: variability of specific hormone binding in vitro. J Endocrinol 1992;134:397-404.
4. Gado K, Pallinger E, Kovacs P, et al. Prolactin influences proliferation and apoptosis of a human IgE secreting myeloma cell line, U266. Immunol Lett 2002;82:191-6.
5. Bernstein L, Ross RK. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 1992;52:5510-5.
6. Cerhan JR, Vachon CM, Habermann TM, et al. Hormone replacement therapy and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 2002;11:1466-71.
7. Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG. No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psychotropics (Netherlands). Cancer Causes Control 2003;14:639-44.
8. Nelson RA, Levine AM, Bernstein L. Reproductive factors and risk of intermediate- or high-grade B-cell non-Hodgkin's lymphoma in women. J Clin Oncol 2001;19:1381-7.
9. Brennan P, Hajeer A, Ong KR, et al. Allelic markers close to prolactin are associated with HLA-DRB1 susceptibility alleles among women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 1997;40:1383-6.
10. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 1996;17:639-69.
11. Stevens A, Ray D, Alansari A, et al. Characterization of a prolactin gene polymorphism and its associations with systemic lupus erythematosus. Arthritis Rheum 2001;44:2358-66.
12. Carey AH, Waterworth D, Patel K, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994;3:1873-6.
13. Bergman-Jungestrom M, Gentile M, Lundin AC, Wingren S. Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer 1999;84:350-3.
14. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE. Cytochrome P 450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998;58:585-7.
15. Gsur A, Bernhofer G, Hinteregger S, et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000;87:434-7.
16. Kittles RA, Panguluri RK, Chen W, et al. Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol Biomarkers Prev 2001;10:943-7.
17. Hong CC, Thompson HJ, Jiang C, et al. Association between the T27C polymorphism in the cytochrome P 450 c17α (CYP17) gene and risk factors for breast cancer. Breast Cancer Res Treat 2004;88:217-30.
18. Sharp L, Cardy AH, Cotton SC, Little J. CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors, a HuGE review. Am J Epidemiol 2004;160:729-40.
19. Huh MM, Friedhoff AJ. Multiple molecular forms of catechol-O-methyl- transferase. Evidence for two distinct forms, and their purification and physical characterization. J Biol Chem 1979;254:299-308.
20. Dawling S, Roodi N, Mernaugh RL, Wang X, Pari FF. Catechol-O- methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res 2001;61:6716-22.
21. Syvanen AC, Tilgmann C, Rinne J, Ulmanen I. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 1997;7:65-71.
22. Holly EA, Bracci PM. Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco. Am J Epidemiol 2003;158:316-27.
23. Holly EA, Lele C. Non-Hodgkin's lymphoma in HIV-positive and HIV-negative homosexual men in the San Francisco Bay Area: allergies, prior medication use, and sexual practices. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:211-22.
24. Holly EA, Lele C, Bracci PM, McGrath MS. Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 1999;150:375-89.
25. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
26. Jaffe ES, Harris NL, Stein H, Vardiman JV, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon: 2001.
27. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of linkage disequilibrium and haplotype maps. Bioinformatics 2005;21:263-5. Epub 2004 Aug 5.
28. Stram DO, Leigh Pearce C, Bretsky P, et al. Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 2003;55:179-90.
29. Zaykin DV, Westfall PH, Young SS, Karnoub MA, Wagner MJ, Ehm MG. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered 2002;53:79-91.
30. Loukola A, Chadha M, Penn SG, et al. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2. Eur J Hum Genet 2004;12:321-32.
31. Skibola CF, Lightfoot T, Agana L, et al. Polymorphisms in cytochrome P 450 17A1 and risk of non-Hodgkin lymphoma. Br J Haematol 2005;129:618-21.
32. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92:1240-51.
33. Nakajin S, Shively JE, Yuan PM, Hall PF. Microsomal cytochrome P-450 from neonatal pig testis: two enzymatic activities (17α-hydroxylase and c17,20-lyase) associated with one protein. Biochemistry 1981;20:4037-42.
34. Conley AJ, Bird IM. The role of cytochrome P 450 17α-hydroxylase and 3>-hydroxysteroid dehydrogenase in the integration of gonadal and adrenal steroidogenesis via the δ5 and δ4 pathways of steroidogenesis in mammals. Biol Reprod 1997;56:789-99.
35. Ntais C, Polycarpou A, Ioannidis JP. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003;12:120-6.
36. Worda C, Sator MO, Schneeberger C, Jantschev T, Ferlitsch K, Huber JC. Influence of the catechol-O-methyltransferase (COMT) codon 158 polymorphism on estrogen levels in women. Hum Reprod 2003;18:262-6.
37. Tworoger SS, Chubak J, Aiello EJ, et al. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13:94-101.
38. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 1999;59:4870-5.
39. Lavigne JA, Helzlsouer KJ, Huang HY, et al. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 1997;57:5493-7.
40. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999;39:19-52.
41. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81-6.
42. Bray NJ, Buckland PR, Williams NM, et al. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet 2003;73:152-61.
43. Bergquist J, Josefsson E, Tarkowski A, Ekman R, Ewing A. Measurements of catecholamine-mediated apoptosis of immunocompetent cells by capillary electrophoresis. Electrophoresis 1997;18:1760-6.
44. Basu S, Dasgupta PS. Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol 2000;102:113-24.
45. Sabharwal P, Glaser R, Lafuse W, et al. Prolactin synthesized and secreted by human peripheral blood mononuclear cells: an autocrine growth factor for lymphoproliferation. Proc Natl Acad Sci U S A 1992;89:7713-6.
46. Stevens A, Ray DW, Worthington J, Davis JR. Polymorphisms of the human prolactin gene-implications for production of lymphocyte prolactin and systemic lupus erythematosus. Lupus 2001;10:676-83.
47. Yu-Lee L, Luo G, Moutoussamy S, Finidori J. Prolactin and growth hormone signal transduction in lymphohaemopoietic cells. Cell Mol Life Sci 1998;54:1067-75.
48. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 2002;109:1625-33.
49. Peeva E, Michael D, Cleary J, Rice J, Chen X, Diamond B. Prolactin modulates the naive B cell repertoire. J Clin Invest 2003;111:275-83.
50. Buckley AR. Prolactin, a lymphocyte growth and survival factor. Lupus 2001;10:684-90.
51. Coffey RN, Watson RW, O'Neill AJ, Mc Eleny K, Fitzpatrick JM. Androgen-mediated resistance to apoptosis. Prostate 2002;53:300-9.
52. Zhang Y, Holford TR, Leaderer B, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004;15:419-28.
53. Wiegratz I, Kutschera E, Lee JH, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 2003;67:25-32.
54. Altieri A, Callus S, Franceschi S, et al. Hormone replacement therapy and risk of lymphomas and myelomas. Eur J Cancer Prev 2004;13:349-51.
55. Holly EA, Gautam M, Bracci PM. Comparison of interviewed and non-interviewed non-Hodgkin's lymphoma (NHL) patients in the San Francisco Bay Area. Ann Epidemiol 2002;12:419-25.